Free Newsletter
New warning for off-label Fentora
The FDA issued a warning yesterday on Fentora, the Cephalon painkiller recently linked to three deaths. All three stemmed from off-label use of the fentanyl drug, which is approved only for treatment of breakthrough cancer pain.
Cephalon had warned doctors two weeks ago of the risk of fatal overdose with Fentora. But the company may have played a role in pushing off-label prescriptions. Since 2004, Cephalon has drawn scrutiny from state and federal prosecutors, and from a Congressional oversight committee, for allegedly promoting off-label uses of several drugs, including Fentora.
- see the FDA warning
- read the article from the Philadelphia Inquirer
Related Articles:
Red flags raised on Fentora misuse. Report
FDA approves Fentora for cancer pain. Report
Cephalon shares jump on Fentora decision. Report
Cephalon takes heat for off-label narcotic promotion. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: